Matthias Staufenbiel,

Matthias Staufenbiel,'s AcademicInfluence.com Rankings

Biology

#12286

World Rank

#15752

Historical Rank

Neuroscience

#2046

World Rank

#2103

Historical Rank

biology Degrees

Download Badge

Biology

Matthias Staufenbiel,'s Degrees

PhD Neuroscience University of California, San Francisco
Bachelors Biology Stanford University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Matthias Staufenbiel, Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Matthias Staufenbiel,'s Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models (2010) (1586)
Transmission and spreading of tauopathy in transgenic mouse brain (2009) (1529)
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. (1997) (1478)
Exogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host (2006) (929)
Clusters of Hyperactive Neurons Near Amyloid Plaques in a Mouse Model of Alzheimer's Disease (2008) (845)
Brain homogenates from human tauopathies induce tau inclusions in mouse brain (2013) (618)
Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis (1998) (530)
Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression (2006) (526)
Neuron loss in APP transgenic mice (1998) (515)
Innate immune memory in the brain shapes neurological disease hallmarks (2018) (513)
Peripherally Applied Aβ-Containing Inoculates Induce Cerebral β-Amyloidosis (2010) (489)
Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer’s disease (2012) (474)
Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. (1999) (398)
Aβ is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis (2004) (378)
Therapeutic approaches to Alzheimer's disease. (2006) (353)
Association of microglia with amyloid plaques in brains of APP23 transgenic mice. (1999) (340)
Reactive glia in the injured brain acquire stem cell properties in response to sonic hedgehog. [corrected]. (2013) (327)
Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Aβ production in APP23 transgenic mice (2003) (327)
Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice* (2005) (326)
Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy (2002) (322)
Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models (2008) (319)
The LPS receptor (CD14) links innate immunity with Alzheimer's disease (2004) (316)
Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. (2005) (314)
Formation and maintenance of Alzheimer's disease β-amyloid plaques in the absence of microglia (2009) (309)
Cognitive and Physical Activity Differently Modulate Disease Progression in the Amyloid Precursor Protein (APP)-23 Model of Alzheimer’s Disease (2006) (308)
Deletion of tumor necrosis factor death receptor inhibits amyloid β generation and prevents learning and memory deficits in Alzheimer's mice (2007) (303)
Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography (2007) (293)
In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe (2005) (289)
Age‐dependent cognitive decline in the APP23 model precedes amyloid deposition (2003) (283)
Spontaneous Hemorrhagic Stroke in a Mouse Model of Cerebral Amyloid Angiopathy (2001) (281)
Locus Ceruleus Degeneration Promotes Alzheimer Pathogenesis in Amyloid Precursor Protein 23 Transgenic Mice (2006) (278)
Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases (2016) (264)
Formation and maintenance of Alzheimer’s disease beta-amyloid plaques in the absence of microglia (2010) (255)
Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera (1995) (255)
Comparative Analysis of Amyloid-β Chemical Structure and Amyloid Plaque Morphology of Transgenic Mouse and Alzheimer's Disease Brains* (2001) (254)
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study (2012) (251)
Cerebral hemorrhage after passive anti-Abeta immunotherapy. (2002) (242)
Induction of cerebral β-amyloidosis: Intracerebral versus systemic Aβ inoculation (2009) (234)
Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease (2008) (231)
Amyloid-Associated Neuron Loss and Gliogenesis in the Neocortex of Amyloid Precursor Protein Transgenic Mice (2002) (230)
App Gene Dosage Modulates Endosomal Abnormalities of Alzheimer's Disease in a Segmental Trisomy 16 Mouse Model of Down Syndrome (2003) (226)
The Liver X Receptor Ligand T0901317 Decreases Amyloid β Production in Vitro and in a Mouse Model of Alzheimer's Disease* (2004) (223)
Induction of Tau Pathology by Intracerebral Infusion of Amyloid-β-Containing Brain Extract and by Amyloid-β Deposition in APP × Tau Transgenic Mice (2007) (219)
Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. (2007) (214)
Molecular imaging of amyloid beta peptides in mouse brain sections using mass spectrometry. (2002) (208)
Neuronal MicroRNA Deregulation in Response to Alzheimer's Disease Amyloid-β (2010) (207)
Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. (2001) (205)
Age effects on the regulation of adult hippocampal neurogenesis by physical activity and environmental enrichment in the APP23 mouse model of Alzheimer disease (2009) (200)
Cerebral Amyloid Induces Aberrant Axonal Sprouting and Ectopic Terminal Formation in Amyloid Precursor Protein Transgenic Mice (1999) (198)
Soluble Aβ Seeds Are Potent Inducers of Cerebral β-Amyloid Deposition (2011) (196)
Invasion of Hematopoietic Cells into the Brain of Amyloid Precursor Protein Transgenic Mice (2005) (185)
Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer’s disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology (2001) (175)
Cholinergic Changes in the APP23 Transgenic Mouse Model of Cerebral Amyloidosis (2002) (169)
Progressive age-related impairment of cognitive behavior in APP23 transgenic mice (2003) (167)
Neprilysin-sensitive Synapse-associated Amyloid-β Peptide Oligomers Impair Neuronal Plasticity and Cognitive Function* (2006) (165)
Imaging of Peripheral Benzodiazepine Receptor Expression as Biomarkers of Detrimental versus Beneficial Glial Responses in Mouse Models of Alzheimer's and Other CNS Pathologies (2008) (164)
Phosphorylation of Actin-Depolymerizing Factor/Cofilin by LIM-Kinase Mediates Amyloid β-Induced Degeneration: A Potential Mechanism of Neuronal Dystrophy in Alzheimer's Disease (2006) (163)
The Second-Generation Active Aβ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects (2011) (157)
Changes in Amyloid-β and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein (2013) (156)
Amyloid β interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease (2000) (154)
The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. (2005) (152)
Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain DOI 10.1194/jlr.M200071-JLR200 (2002) (150)
Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer’s disease (2017) (149)
The Carboxyl Termini of β-Amyloid Peptides 1-40 and 1-42 Are Generated by Distinct γ-Secretase Activities* (1996) (149)
APP Transgenic Mice Tg2576 Accumulate Aβ Peptides That Are Distinct from the Chemically Modified and Insoluble Peptides Deposited in Alzheimer's Disease Senile Plaques† (2002) (147)
Age-Dependent Cerebrovascular Abnormalities and Blood Flow Disturbances in APP23 Mice Modeling Alzheimer's Disease (2003) (146)
Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. (2000) (143)
Apoptotic Force and Tissue Dynamics During Drosophila Embryogenesis (2008) (143)
Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease (2010) (140)
An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease (2015) (139)
Preparation of nuclear matrices from cultured cells: subfractionation of nuclei in situ (1984) (135)
Induction of Brain-Derived Neurotrophic Factor in Plaque-Associated Glial Cells of Aged APP23 Transgenic Mice (2004) (135)
Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation (2002) (131)
Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. (2007) (131)
Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances (2009) (130)
Extracellular amyloid formation and associated pathology in neural grafts (2003) (128)
Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model (2005) (126)
In Vivo Positron Emission Tomographic Imaging of Glial Responses to Amyloid-β and Tau Pathologies in Mouse Models of Alzheimer's Disease and Related Disorders (2011) (123)
3D-Reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid (2001) (122)
Staged decline of neuronal function in vivo in an animal model of Alzheimer's disease (2012) (121)
Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models (2015) (118)
Expression of human β‐secretase in the mouse brain increases the steady‐state level of β‐amyloid (2002) (112)
Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen (2005) (109)
Compromised Hemodynamic Response in Amyloid Precursor Protein Transgenic Mice (2002) (108)
Different structural systems of the nucleus are targets for SV40 large T antigen (1983) (105)
Electrophoretic Separation of βA4 Peptides (1–40) and (1–42) (1996) (103)
Expression of APP in transgenic mice: a Comparison of neuron-specific promoters (1996) (102)
Cystatin C modulates cerebral β-amyloidosis (2007) (99)
Styrylbenzoxazole Derivatives for In Vivo Imaging of Amyloid Plaques in the Brain (2004) (97)
A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice (2015) (96)
Neuronal Localization of Presenilin-1 and Association with Amyloid Plaques and Neurofibrillary Tangles in Alzheimer’s Disease (1997) (95)
Neurogenesis and alterations of neural stem cells in mouse models of cerebral amyloidosis. (2008) (94)
Mechanistic involvement of the calpain‐calpastatin system in Alzheimer neuropathology (2012) (90)
Expression of complement system components during aging and amyloid deposition in APP transgenic mice (2009) (89)
Dynamics of Aβ Turnover and Deposition in Different β-Amyloid Precursor Protein Transgenic Mouse Models Following γ-Secretase Inhibition (2008) (85)
Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides. (2012) (84)
Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances (2004) (83)
Expression profiling in APP23 mouse brain: inhibition of Aβ amyloidosis and inflammation in response to LXR agonist treatment (2007) (82)
Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice (2013) (82)
The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease (2018) (82)
BACE inhibition-dependent repair of Alzheimer’s pathophysiology (2017) (81)
Cystatin C modulates cerebral beta-amyloidosis. (2007) (81)
Genetic Targeting Aromatase in Male Amyloid Precursor Protein Transgenic Mice Down-Regulates β-Secretase (BACE1) and Prevents Alzheimer-Like Pathology and Cognitive Impairment (2010) (80)
Multiple Factors Contribute to the Peripheral Induction of Cerebral β-Amyloidosis (2014) (80)
Age-Dependent Impairment of Somatosensory Response in the Amyloid Precursor Protein 23 Transgenic Mouse Model of Alzheimer's Disease (2003) (79)
APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. (2002) (78)
Intermediate filament systems are collapsed onto the nuclear surface after isolation of nuclei from tissue culture cells. (1982) (77)
Developmental Regulation of Presenilin-1 Processing in the Brain Suggests a Role in Neuronal Differentiation* (1997) (70)
Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. (2006) (69)
Complex formation of APP with GABAB receptors links axonal trafficking to amyloidogenic processing (2019) (69)
Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing β-amyloid precursor protein (APP) with the Swedish double mutation (APP23) (2003) (68)
Brain Endogenous Estrogen Levels Determine Responses to Estrogen Replacement Therapy via Regulation of BACE1 and NEP in Female Alzheimer’s Transgenic Mice (2013) (67)
Highly potent soluble amyloid-β seeds in human Alzheimer brain but not cerebrospinal fluid. (2014) (67)
Cyclic AMP, but not basic FGF, increases the in vitro survival of mesencephalic dopaminergic neurons and protects them from MPP+‐induced degeneration (1992) (66)
Restricted diffusion in the brain of transgenic mice with cerebral amyloidosis (2004) (64)
Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein (2019) (64)
Neocortical synaptic bouton number is maintained despite robust amyloid deposition in APP23 transgenic mice (2005) (64)
Amyloid‐β protein (Aβ) Glu11 is the major β‐secretase site of β‐site amyloid‐β precursor protein‐cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis (2013) (63)
Long-Term Treatment of Thalidomide Ameliorates Amyloid-Like Pathology through Inhibition of β-Secretase in a Mouse Model of Alzheimer’s Disease (2013) (63)
Memory deficits in APP23/Abca1+/− mice correlate with the level of Aβ oligomers (2009) (62)
Noninvasive Magnetic Resonance Imaging Detection of Cerebral Amyloid Angiopathy-Related Microvascular Alterations Using Superparamagnetic Iron Oxide Particles in APP Transgenic Mouse Models of Alzheimer's Disease: Application to Passive Aβ Immunotherapy (2011) (59)
Ankyrin is fatty acid acylated in erythrocytes. (1986) (59)
Ankyrin-bound fatty acid turns over rapidly at the erythrocyte plasma membrane (1987) (58)
Occurrence and co-localization of amyloid β-protein and apolipoprotein E in perivascular drainage channels of wild-type and APP-transgenic mice (2007) (57)
Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. (2002) (56)
The Evolution of Aβ Peptide Burden in the APP23 Transgenic Mice: Implications for Aβ Deposition in Alzheimer Disease (2001) (55)
Persistence of Aβ seeds in APP null mouse brain (2015) (55)
Spatial learning and exploration of environmental stimuli in 24-month-old female APP23 transgenic mice with the Swedish mutation (2004) (53)
Magnetic resonance angiography and vascular corrosion casting as tools in biomedical research: application to transgenic mice modeling Alzheimer's disease (2004) (52)
APP23 Mice as a Model of Alzheimer's Disease: An Example of a Transgenic Approach to Modeling a CNS Disorder (2005) (51)
Selective vulnerability of different types of commissural neurons for amyloid beta-protein-induced neurodegeneration in APP23 mice correlates with dendritic tree morphology. (2006) (51)
Macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors with activity in vivo. (2009) (48)
Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy (2002) (48)
Altered ingestive behavior, weight changes, and intact olfactory sense in an APP overexpression model. (2008) (47)
Exposure to 56Fe-Particle Radiation Accelerates Electrophysiological Alterations in the Hippocampus of APP23 Transgenic Mice (2010) (47)
Transgenic Expression of Intraneuronal Aβ42 But Not Aβ40 Leads to Cellular Aβ Lesions, Degeneration, and Functional Impairment without Typical Alzheimer's Disease Pathology (2012) (45)
Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. (2010) (45)
Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life (2020) (44)
Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice (2012) (44)
Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases (2016) (42)
Increased CSF Aβ during the very early phase of cerebral Aβ deposition in mouse models (2015) (42)
Electrophoretic separation of betaA4 peptides (1-40) and (1-42). (1996) (41)
Aged APP23 mice show a delay in switching to the use of a strategy in the Barnes maze (2007) (41)
Early‐onset axonal pathology in a novel P301S‐Tau transgenic mouse model of frontotemporal lobar degeneration (2015) (41)
Co-expression of truncated and full-length tau induces severe neurotoxicity (2016) (40)
Transgenic Mouse Models of Alzheimer's Disease (2000) (40)
Calpain inhibitor I decreases βA4 secretion from human embryonal kidney cells expressing β-amyloid precursor protein carrying the APP670/671 double mutation (1995) (39)
Fatty acids covalently bound to erythrocyte proteins undergo a differential turnover in vivo. (1988) (39)
Independent effects of intra- and extracellular Abeta on learning-related gene expression. (2009) (38)
Vaccination with Aβ-Displaying Virus-Like Particles Reduces Soluble and Insoluble Cerebral Aβ and Lowers Plaque Burden in APP Transgenic Mice1 (2009) (38)
Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models (2005) (38)
β-Amyloid Peptide Variants in Brains and Cerebrospinal Fluid from Amyloid Precursor Protein (APP) Transgenic Mice (2011) (38)
Interruption of [beta]-Catenin Signaling Reduces Neurogenesis in Alzheimer's Disease Brains (2008) (37)
Nuclear matrix preparations from liver tissue and from cultured vertebrate cells: differences in major polypeptides. (1983) (37)
A novel imaging probe for in vivo detection of neuritic and diffuse amyloid plaques in the brain (2007) (37)
Vessel ultrastructure in APP23 transgenic mice after passive anti-Aβ immunotherapy and subsequent intracerebral hemorrhage (2007) (37)
Laser microdissection reveals regional and cellular differences in GFAP mRNA upregulation following brain injury, axonal denervation, and amyloid plaque deposition (2004) (36)
Aggressive male APP23 mice modeling behavioral alterations in dementia. (2006) (36)
Identification of the 5‐Hydroxytryptamine2C Receptor as a 60‐kDa N‐Glycosylated Protein in Choroid Plexus and Hippocampus (1995) (35)
Conversion of Synthetic Aβ to In Vivo Active Seeds and Amyloid Plaque Formation in a Hippocampal Slice Culture Model (2016) (35)
Mood and male sexual behaviour in the APP23 model of Alzheimer's disease (2007) (34)
Amyloid precursor protein truncated at any of the γ‐secretase sites is not cleaved to β‐amyloid (1996) (34)
Age‐dependent time course of cerebral brain‐derived neurotrophic factor, nerve growth factor, and neurotrophin‐3 in APP23 transgenic mice (2008) (34)
Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition (2017) (33)
Oral administration of synthetic retinoid Am80 (Tamibarotene) decreases brain beta-amyloid peptides in APP23 mice. (2009) (33)
Regional brain cytochrome oxidase activity in β-amyloid precursor protein transgenic mice with the swedish mutation (2003) (32)
Amyloid deposition in APP23 mice is associated with the expression of cyclins in astrocytes but not in neurons (2003) (32)
Transgenic Approaches to Model Alzheimer's Disease (2000) (31)
Progressive reorganization of the host cell cytoskeleton during adenovirus infection (1986) (31)
β‐Secretase cleavage is not required for generation of the intracellular C‐terminal domain of the amyloid precursor family of proteins (2010) (30)
Aβ seeding potency peaks in the early stages of cerebral β‐amyloidosis (2017) (29)
Impairment of Adolescent Hippocampal Plasticity in a Mouse Model for Alzheimer's Disease Precedes Disease Phenotype (2008) (29)
Amyloid Beta Annular Protofibrils in Cell Processes and Synapses Accumulate with Aging and Alzheimer-Associated Genetic Modification (2009) (29)
Conformations of synthetic beta peptides in solid state and in aqueous solution: relation to toxicity in PC12 cells. (1996) (28)
Genetic deletion of TNFRII gene enhances the Alzheimer-like pathology in an APP transgenic mouse model via reduction of phosphorylated IκBα. (2014) (28)
Membrane-Anchored Aβ Accelerates Amyloid Formation and Exacerbates Amyloid-Associated Toxicity in Mice (2013) (27)
Excitatory synaptic transmission is depressed in cultured hippocampal neurons of APP/PS1 mice (2009) (27)
Amyloid Precursor Protein Mutation Disrupts Reproductive Experience-Enhanced Normal Cognitive Development in a Mouse Model of Alzheimer's Disease (2014) (27)
Deficiency of patched 1-induced Gli1 signal transduction results in astrogenesis in Swedish mutated APP transgenic mice. (2014) (26)
The Swedish APP mutation alters the effect of genetically reduced BACE1 expression on the APP processing (2011) (23)
Assembly of protein 4.1 during chicken erythroid differentiation (1986) (23)
Chronic Administration of Anti-Stroke Herbal Medicine TongLuoJiuNao Reduces Amyloidogenic Processing of Amyloid Precursor Protein in a Mouse Model of Alzheimer’s Disease (2013) (22)
Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid β-peptides. (2013) (22)
Impulsivity, decreased social exploration, and executive dysfunction in a mouse model of frontotemporal dementia (2016) (22)
APP23 mice display working memory impairment in the plus-shaped water maze (2006) (21)
Impaired hypoxic tolerance and altered protein binding of NADH in presymptomatic APP23 transgenic mice (2002) (20)
Distinct Processing of Endogenous and Overexpressed Recombinant Presenilin 1 (1997) (20)
Early Aβ reduction prevents progression of cerebral amyloid angiopathy (2019) (19)
Highly potent intracellular membrane-associated Aβ seeds (2016) (18)
Rapid Cerebral Amyloid Binding by Aβ Antibodies Infused into β-Amyloid Precursor Protein Transgenic Mice (2010) (17)
Proteomic 2-D DIGE profiling of APP23 transgenic mice brain from pre-plaque and plaque phenotypes. (2008) (17)
Amyloid precursor protein truncated at any of the gamma-secretase sites is not cleaved to beta-amyloid. (1996) (17)
BACE1 and Mutated Presenilin-1 Differently Modulate Aβ40 and Aβ42 Levels and Cerebral Amyloidosis in APPDutch Transgenic Mice (2007) (17)
Calpastatin modulates APP processing in the brains of β-amyloid depositing but not wild-type mice (2012) (17)
Increased exploratory activity of APP23 mice in a novel environment is reversed by siRNA (2008) (15)
Impact of amyloid β aggregate maturation on antibody treatment in APP23 mice (2015) (14)
E22Q-mutant Abeta peptide (AbetaDutch) increases vascular but reduces parenchymal Abeta deposition. (2009) (14)
Evaluation of the APP23-model for Alzheimer's disease in the odour paired-associate test for hippocampus-dependent memory (2008) (13)
Membrane interactions of simian virus 40 large T-antigen: influence of protein sequences and fatty acid acylation (1984) (13)
Longitudinal noninvasive magnetic resonance imaging of brain microhemorrhages in BACE inhibitor–treated APP transgenic mice (2016) (13)
Age-dependent changes in noradrenergic locus coeruleus system in wild-type and APP23 transgenic mice (2009) (13)
The type of Aβ-related neuronal degeneration differs between amyloid precursor protein (APP23) and amyloid β-peptide (APP48) transgenic mice (2013) (13)
Thrombolysis in Experimental Cerebral Amyloid Angiopathy and the Risk of Secondary Intracerebral Hemorrhage (2014) (13)
Vaccination with Abeta displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice (2009) (12)
Calpain inhibitor I decreases beta A4 secretion from human embryonal kidney cells expressing beta-amyloid precursor protein carrying the APP670/671 double mutation. (1995) (12)
Electrophoretic separation and immunoblotting of aβ(1-40) and aβ (1-42). (2000) (11)
Role of hippocalcin in mediating Aβ toxicity. (2012) (9)
Endogenous murine Aβ increases amyloid deposition in APP23 but not in APPPS1 transgenic mice (2015) (8)
TRANSGENIC ANIMAL MODELS IN THE DEVELOPMENT OF THERAPEUTIC STRATEGIES FOR ALZHEIMER’S DISEASE (1998) (7)
Discovery of amino-1,4-oxazines as potent BACE-1 inhibitors. (2018) (7)
Erratum: Reactive glia in the injured brain acquire stem cell properties in response to sonic hedgehog (Cell Stem Cell (2013) 12 426-439)) (2013) (7)
Transgenic expression of β1 antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice (2013) (7)
BACE1 and mutated presenilin-1 differently modulate Abeta40 and Abeta42 levels and cerebral amyloidosis in APPDutch transgenic mice. (2007) (6)
Signatures of glial activity can be detected in the CSF proteome (2022) (5)
Amyloid β peptide is not a candidate for the neurotrophic activities released from chromaffin cells (1998) (5)
A beta peptide deposition in the brains of transgenic mice: evidence for a key event in Alzheimer's disease pathogenesis. (1998) (5)
Amyloid-β in the Cerebrospinal Fluid of APP Transgenic Mice Does not Show Prion-like Properties. (2015) (4)
Innate immune memory in the brain shapes neurological disease hallmarks (2018) (4)
Aβ peptide deposition in the brains of transgenic mice: evidence for a key event in Alzheimer's disease pathogenesis (1998) (4)
[Genetic predisposition for Alzheimer's disease]. (1995) (4)
Synthesis of the Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor NB-360. (2021) (4)
574 Localization and functional significance of presenilin S182 (1996) (3)
Using β-Secretase Inhibitors to Distiguish the Generation of the Aβ Peptides Terminating at Val-40 and Ala-42. (2000) (3)
Amyloid beta-protein and apolipoprotein E co-localise within perivascular drainage channels in wild-type and APP-transgenic mice (2006) (3)
Statin Therapy and the Development of Cerebral Amyloid Angiopathy—A Rodent in Vivo Approach (2016) (3)
Cloning and characterization of restriction fragments of phage Mu DNA (1983) (3)
HIGHLY POTENT SOLUBLE Aβ SEEDS IN HUMAN ALZHEIMER BRAIN BUT NOT CEREBROSPINAL FLUID (2014) (3)
O1-06-01 Immunization with Aβ1-6 coupled to the virus-like particle Qβ (CAD106) efficiently removes β-amyloid without inducing Aβ-reactive T-cells (2006) (3)
Subcellular Localization of Simian Virus 40 T-Antigen (1983) (3)
Does alternative exon usage contribute to serotonin receptor heterogeneity? (1991) (3)
A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice (2015) (3)
Short Communication E22Q-Mutant A (cid:1) Peptide (A (cid:1) Dutch) Increases Vascular but Reduces Parenchymal A (cid:1) Deposition (2009) (2)
Histochemical localization of Aβ peptide in APP 23 mouse brain (1998) (2)
Fatty acylation of erythrocyte proteins. (1989) (2)
[Mechanisms of Alzheimer's disease : Neuronal hyperactivity and hypoactivity as new therapeutic targets]. (2016) (2)
Pathogenesis and Mechanism of Cerebral Amyloidosis in APP Transgenic Mice (2001) (2)
Mechanism and pathogenesis of cerebral amyloidosis in APP transgenic mice (2000) (2)
P2-062 Induction of brain-derived neurotrophic factor (BDNF) in plaque-associated glial cells of aged APP23 transgenic mice (2004) (2)
CSF beta-amyloid 42 and t-tau profile in murine models of cerebral beta-amyloidosis (2013) (1)
THE BACE INHIBITOR NB-360 HAS EXCELLENT BRAIN PENETRATION AND EFFICACY ON AMYLOID-B LOAD IN ANIMAL MODELS (2014) (1)
Title An aberrant sugar modification of BACE 1 blocks its lysosomal targeting inAlzheimer ' s disease (2019) (1)
P2-108 Stages of amyloid deposition and plaque types in different APP transgenic mice as compared to AD (2004) (1)
P68 ALTERED CIRCADIAN LOCOMOTOR ACTIVITY IN APP23 MICE: A MODEL FOR BPSD DISTURBANCES (2004) (1)
PRECLINICAL PHARMACOLOGY OF BACE INHIBITOR CNP520 (2016) (1)
Identification and Characterization of Proteins Undergoing Reversible Fatty Acid Acylation (1988) (1)
Reactive astrogliosis enhances pyroGlu-Aβ formation via up regulation of glutaminyl cyclase, and reduced neprilysin activity exacerbates this process (2010) (1)
Strong parenchymal amyloid reduction following CAD106 immunotherapy is associated with an increase in vascular Aβ but not microhemorrhages (2009) (1)
Distinct Domains of Simian Virus 40 Large T Antigen Mediate Its Association with Different Cellular Targets (1986) (1)
P1-008 Brain estrogen deficiency accelerates amyloid plaque formation in Alzheimer’s disease animal model (2006) (1)
P1-029 Occurrence of amyloid β-protein and co-localization with apolipoprotein E in perivascular drainage channels of wild-type and APP-transgenic mice (2006) (1)
Title Global brain delivery of neprilysin gene by intravascular administration ofAAV vector in mice (2019) (0)
Mice Overexpressing Amyloid Precursor Protein and Tau in the Cerebrospinal Fluid of Transgenic β Changes in Amyloid - (2013) (0)
Various inoculation routes of Aβ-containing brain extract in APP-tg mice (2010) (0)
Soluble Aβ in APP23 transgenic mice induces degeneration of layer III pyramidal neurons with ramified dendritic tree (2004) (0)
[Genetic predisposition to Alzheimer's disease]. (1997) (0)
P4-332 LXR ligand treatment in vitro and in vivo is followed by ABCA1 upregulation and decrease in AB secretion (2004) (0)
The role of oscillatory synchronization in the decoding of temporal information in PN assemblies (2002) (0)
Early-onset Axonal Pathology in a Novel P301S-Tau Transgenic Mouse Model of Frontotemporal Dementia (2015) (0)
P4-349 Early-stage cerebral amyloidosis as a therapeutic target (2004) (0)
Colloquium C02: Microglial Responses to Injury & Strategies for Managing Them (2003) (0)
Extracellular but not intracellular A beta-deposits induce dendrite tree degeneration of frontocentral commissural neurons in mouse models of Alzheimer's disease (2008) (0)
Molecular arrangement of amyloid beta antigenic (2002) (0)
Alzheimer’s disease‐related necroptotic pathology: An exclusive presence of the necrosome in granulovacuolar degeneration inclusions in human and transgenic mouse brains (2020) (0)
P1-039 Hierarchical deposition of amyloid β-protein (Aβ) deposits in the brain results from increasing cerebral Aβ-levels (2006) (0)
The active Aβ immunotherapy CAD106 increases plasma Aβ in monkeys (2010) (0)
50th Annual Meeting of the German Society of Neuropathology and Neuroanatomy, Clinical Neuropatholy - State of the Art, Graz, Austria, October 5-8, 2005 (2005) (0)
S3-01-06 Cerebral amyloid angiopathy in transgenic mouse models (2004) (0)
P1-417: How does elimination of TNF receptor affect amyloid-β protein generation and prevent learning and memory deficits in transgenic Alzheimer's mice? (2008) (0)
Dystriphic neurites in plaque-like Aβdeposits in mice double transgenic for the APP 670 671 mutation and the human four-repeat tau protein (2000) (0)
The type of Aβ-related neuronal degeneration differs between amyloid precursor protein (APP23) and amyloid β-peptide (APP48) transgenic mice (2013) (0)
Reduced neprilysin activity is associated with increased formation of pyroglutamylated amyloid-β peptides through upregulation of aminopeptidases and glutaminyl cyclase in brain (2009) (0)
P1-079: Calpain inhibition by calpastatin overexpression reduces β-amyloid deposition in an APP transgenic mouse (2008) (0)
Transgenic Mice and Lowers Plaque Burden in β Cerebral A Particles Reduces Soluble and Insoluble-Displaying Virus-Like β Vaccination with (2009) (0)
Toxicity of amylin, Abeta and tau: Proteomics, miRNA analysis and mitochondrial dysfunction (2010) (0)
Cerebral hemorrhage and amytoid-β [3] (2003) (0)
P1-035: Exogenous induction of Abeta-amyloidosis: Peripheral and stainless-steel-wire inoculations (2008) (0)
Vaccine compositions containing the amyloid beta 1-6 Antigen Arrays (2003) (0)
Cerebral amyloid angiopathy in transgenic mice modelling Alzheimer ’ s disease studied non-invasively by MRI (2009) (0)
GLYCOSYLATION REGULATES DEGRADATION OF BACE1 IN LYSOSOME (2014) (0)
Effect of different estrogens on BACE in Alzheimer's disease (2011) (0)
P1-036 Genetic modulation of vascular amyloid in APPDutch mice (2006) (0)
DEEP PROTEOME ANALYSIS IN CEREBROSPINAL FLUID OF MOUSE MODELS FOR NEURODEGENERATIVE DISEASES SUGGESTS A PANEL OF NOVEL BIOMARKERS RELATED TO MICROGLIA ACTIVATION (2019) (0)
Aβ reduction at early disease stages prevents progression of cerebral amyloid angiopathy in a mouse model ofhereditary cerebral hemorrhage with amyloidosis - Dutch type (2019) (0)
Accumulation of amyloid beta protein causes a hierarchical degeneration of commissural neurons in the frontal cortex (2005) (0)
Dynamics of A (cid:1) Turnover and Deposition in Different (cid:1) -Amyloid Precursor Protein Transgenic Mouse Models Following (cid:2) -Secretase Inhibition □ (2008) (0)
Vaccine compositions containing amyloid beta antigen arrays 1-6 (2003) (0)
P1-097 The role of cystatin C in cerebral amyloidosis: New insights from transgenic mouse models (2006) (0)
Brain Endogenous Estrogen Levels Determine Responses to Estrogen Replacement Therapy via Regulation of BACE1 and NEP in Female Alzheimer’s Transgenic Mice (2012) (0)
Oral Presentations OP1: From the Why's to Possible Treatment of Some Neural Problems (2003) (0)
Experimental evidence for temporal uncoupling of brain Aβ deposition and neurodegenerative sequelae (2022) (0)
The sequence of amyloid beta-protein (A beta) deposition in the human brain corresponds to that in the APP-transgenic mouse model and is related to increasing A beta-levels in the brain and to neurodegeneration (2006) (0)
P2-064 Rapid Aβ turnover and reduction of amyloid plaque formation after acute and long-term inhibition of Aβ generation in APP23 mice (2004) (0)
P1-116 NEUROFILAMENT LIGHT LEVELS IN THE CEREBROSPINAL FLUID ARE UNCOUPLED OFAMYLOIDOSIS IN LATE STAGE PATHOGENESIS OFAPP TRANSGENIC MICE (2018) (0)
P1-434: Accumulation of Aβ starting with pyroglutamate at position 3 in the brain and its impact on amyloid pathology of Alzheimer's disease (2008) (0)
INACTIVATION OF PATHOGENIC Aβ SEEDS AT PRE-AMYLOID DISEASE STAGES (2019) (0)
Impact of amyloid β aggregate maturation on antibody treatment in APP23 mice (2015) (0)
Amyloid Precursor Protein Mutation Disrupts Reproductive Experience-Enhanced Normal Cognitive Development in a Mouse Model of Alzheimer's Disease (2013) (0)
P1-406: MicroRNA deregulation in Alzheimer's disease models (2008) (0)
P1-031 Age-related cerebral changes of brain-derived neurotrophic factor in a model of Alzheimer’s disease in APP23 transgenic mice (2006) (0)
SUPPRESSION OF TAU INCREASE IN CEREBROSPINAL FLUID OF APP TRANSGENIC MICE PROVIDES EVIDENCE FOR DOWNSTREAM EFFECT OF BACE1 INHIBITION (2016) (0)
P4-104 Hypoxia facilitates Alzheimer’s disease pathogenesis (2006) (0)
Seeded beta-amyloid in long-term hippocampal slice cultures (2013) (0)
P3-308 Pathology study in wild type, APP23 and alpha synuclein transgenic animals overexpressing human tau P301S (2006) (0)
P67 OBJECTRECOGNITION IMPAIRMENT IN Fmr1 KNOCKOUTMICE ISREVERSEDBYAMPHETAMINE: INVOLVEMENTOFDOPAMINE INTHEMEDIAL PREFRONTAL CORTEX (2004) (0)
P4-010 Cognitive impairment caused by neprilysin-sensitive Aβ-oligomers in mice (2006) (0)
P1-061 Accelerated neurodegeneration in mice expressing mutant tau and APP (2006) (0)
The LXR ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer’s disease (2004) (0)
Tau-targeted treatment of Alzheimer's disease and related disorders (2010) (0)
Independent Effects of Intra- and Extracellular A (cid:1) on Learning-Related Gene Expression (2009) (0)
Cerebral amyloid angiopathy is associated with a reduced capillary density and disturbances in cerebral blood flow (2007) (0)
P4-689 INACTIVATION OF PATHOGENIC Ab SEEDS AT PRE-AMYLOID DISEASE STAGES (2019) (0)
P1-067 Relative impact of vascular versus parenchymal amyloid on synaptic plasticity-related gene induction (2006) (0)
Soluble forms of A beta alter layer III pyramidal neurons with a ramified dendritic tree in APP23-transgenic mice (2004) (0)
Mechanisms of passive vaccination against amyloid β-protein in APP23 mice (2014) (0)
72 Characterization of S182 (presenilin 1) and its effect on ßA4 (1996) (0)
P1-074 Eating & drinking in an APP hyperexpression model (2006) (0)
A-beta peptide signatures in brains, CSF and blood plasma from APP23 transgenic mice (2007) (0)
P4-027 Altered gene expression in meningeal vessels of APP23 transgenic mice (2006) (0)
PREVENTION OF CEREBRAL AMYLOID ANGIOPATHY IN A MOUSE MODEL OF HEREDITARY CEREBRAL HEMORRAGE WITH AMYLOIDOSIS-DUTCH TYPE (2017) (0)
Matrix molecular antigen presenting a beta amyloid. (2002) (0)
Matrices d'antigenes amyloides beta1-6 (2003) (0)
Complex formation of APP with GABAB receptors links axonal trafficking to amyloidogenic processing (2019) (0)
P3-282 Expression of complement system components during amyloid deposition in APP transgenic mice (2006) (0)
The role of dispersible amyloid β-protein aggregates for Alzheimer’s disease and its therapy (2012) (0)
Inflammatory processes in the APP23 mouse model of Alzheimer's disease (2000) (0)
Characterization of different transgenic mouse lines, overexpressing the FAD-linked human presenilin 1 CDNA (2000) (0)
Elevated levels of soluble, high molecular weight SDS-denaturable Aβ-aggregates are associated with dendritic degeneration in APP-transgenic mouse models (2011) (0)
NEUROFILAMENT LIGHT LEVELS IN THE CEREBROSPINAL FLUID ARE UNCOUPLED OF AMYLOIDOSIS IN LATE STAGE PATHOGENESIS OF APP TRANSGENIC MICE (2018) (0)
P1-071: High resolution 1d and 2d analysis of A-beta peptides in plasma, Csf and brains of APP23 transgenic mice (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Matthias Staufenbiel,?

Matthias Staufenbiel, is affiliated with the following schools:

Matthias Staufenbiel,'s Academic­Influence.com Rankings